Weekly stock picks by Religare Broking: Buy Ajanta Pharma, Dabur India

Ajanta Pharma's stock has seen a fresh breakout from the trading range of roughly 1350-1480 levels

technicals
Religare Broking Mumbai
2 min read Last Updated : Mar 04 2020 | 8:23 AM IST
Buy Ajanta Pharma Limited

Last Close: Rs 1,477.50

Initiation range: Rs 1,460-1,470

Target: Rs 1,550

Stop loss: Rs 1,420

Unlike the majority pharma counters, AJANTHPHARM has been witnessing steady up move after the breakout from its one and a half year long consolidation phase. In yesterday's session, the stock saw a fresh breakout from the trading range of roughly 1350-1480 levels and is likely to see a fresh surge. We thus advise traders to create fresh longs as per the given levels.
 

Also Read

Buy Indraprastha Gas Limited

Last Close: Rs 448

Initiation range: Rs 442-446

Target: Rs 470

Stop loss: Rs 432

IGL has been witnessing profit taking for the last three weeks, after making a record high at 534.20 on February 7, 2020. It has reached closer to the support zone of 100 EMA on the daily chart and indications are in the favor of marginal consolidation around that zone, followed by the resumption of the uptrend. Traders can accumulate in the given range. 
 
Buy Dabur India Limited

Last Close: Rs 506.60

Initiation range: Rs 502-505

Target: Rs 528

Stop loss: Rs 490

Dabur, after the sharp surge from 446 to 523 levels, has retraced marginally of late and is currently hovering in a narrow range around the support zone placed around 50 EMA on the daily chart. Indications are in the favor of the fresh up move in the near future. We thus advise accumulating within the mentioned zone.
 
Sell March Futures of RBL Bank Limited

Last Close: Rs 289.80

Initiation range: Rs 293-295

Target: Rs 275

Stop loss: Rs 302

We’re seeing a mixed trend within the private banking pack and RBL Bank is in a downtrend. After forming a new record low at 230.55 level, it witnessed sharp rebound but couldn’t surpass the hurdle of 100 EMA on the daily chart and started drifting lower again. The recent bounce is offering an opportunity for those who missed the chance earlier.
Disclaimer: http://www.religareonline.com/disclaimer

Disclaimer: The analyst may have positions in one or all of the above mentioned stocks

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :technical analysisMarketsAjanta PharmaDabur India

Next Story